Prognostic role of the skeletal musculature in oncology: significance, coherences and clinical implications

Abstract

Background Sarcopenia is defined as a loss of muscle mass and strength as well as decreased physical performance. Method The present study provides a systematic overview of the current literature in regard to the prognostic role of sarcopenia in oncology. Conclusion In oncologic patients, sarcopenia occurs in 39.6 % of cases in a curative setting and in 49.2 % in a palliative setting. Sarcopenia is associated with dose-limiting toxicity. Furthermore, sarcopenia is associated with the occurrence of postoperative complications. Also, reduced muscle mass limits overall survival in most tumors both in a curative and a palliative setting. Therefore, analysis of the skeletal musculature on staging CT should be implemented in the clinical routine in oncology. Key Points:  Citation Format